

IN THE CLAIMS

1. (Currently amended) A modified human fibronectin type III (Fn3) molecule comprising a stabilizing mutation of at least one residue involved in an unfavorable electrostatic interaction as compared to the [[a]] wild-type human Fn3, wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with a neutral or positively charged another amino acid residue.
- 2-3. (Canceled)
4. (Previously presented) The Fn3 of claim 1, wherein Asp 7 or Asp 23, or both, have been substituted with an asparagine (Asn) or lysine (Lys) residue.
- 5-6. (Canceled)
7. (Previously presented) The Fn3 of claim 1, wherein Glu 9 has been substituted with an asparagine (Asn) or lysine (Lys) residue.
8. (Currently amended) The Fn3 of claim 1, wherein Asp 7, Asp 23, and Glu 9 have been substituted with a neutral or positively charged at least one other amino acid residue.
- 9-54. (Canceled)
55. (Currently amended) The Fn3 of claim 1 [[54]], wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with a neutral amino acid residue.
56. (Currently amended) The Fn3 of claim 1 [[54]], wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with a positively charged amino acid residue.

57. (Currently amended) A modified human tenth type III module of fibronectin (FNfn10) molecule comprising a stabilizing mutation of at least one residue involved in an unfavorable electrostatic interaction as compared to the [[a]] wild-type human FNfn10 molecule, wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with a neutral or positively charged another amino acid residue.
58. (Canceled)
59. (Currently amended) The modified FNfn10 of claim 57 [[58]], wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with a neutral amino acid residue.
60. (Currently amended) The modified FNfn10 of claim 57 [[58]], wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with a positively charged amino acid residue.
61. (Currently amended) The modified FNfn10 of claim 57 [[58]], wherein amino acid residues 7 or 23, or both, have been substituted with an asparagine (Asn) or lysine (Lys) residue.
62. (Currently amended) The modified FNfn10 of claim 57 [[58]], wherein amino acid residue 9 has been substituted with an asparagine (Asn) or lysine (Lys) residue.
63. (Currently amended) The modified FNfn10 of claim 57, wherein amino acid residues 7, 9 and 23 have been substituted with a neutral or positively charged at least one other amino acid residue.
64. (New) The Fn3 of claim 1, wherein amino acid residue 1 is Val.
65. (New) The Fn3 of claim 1, wherein amino acid residue 6 is Arg.
66. (New) The Fn3 of claim 55, wherein Asp 7 is substituted with a neutral amino acid.

67. (New) The Fn3 of claim 56, wherein Asp 7 is substituted with a positive amino acid.
68. (New) The Fn3 of claim 55, wherein Glu 9 is substituted with a neutral amino acid.
69. (New) The Fn3 of claim 56, wherein Glu 9 is substituted with a positive amino acid.
70. (New) The Fn3 of claim 55, wherein Asp 23 is substituted with a neutral amino acid.
71. (New) The Fn3 of claim 56, wherein Asp 23 is substituted with a positive amino acid.
72. (New) The Fn3 of claim 4, wherein Asp 7 is substituted with an Asn residue.
73. (New) The Fn3 of claim 4, wherein Asp 7 is substituted with a Lys residue.
74. (New) The Fn3 of claim 7, wherein Glu 9 is substituted with an Asn residue.
75. (New) The Fn3 of claim 7, wherein Glu 9 is substituted with a Lys residue.
76. (New) The Fn3 of claim 4, wherein Asp 23 is substituted with an Asn residue.
77. (New) The Fn3 of claim 4, wherein Asp 23 is substituted with a Lys residue.
78. (New) The Fn3 of claim 57, wherein amino acid residue 1 is Val.
79. (New) The Fn3 of claim 57, wherein amino acid residue 6 is Arg.